New York
NEW YORK, Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
From
To
Banking Financial Services
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.Â
New York
Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure failures that preceded a $102.09 per-share decline from the Class Period high. This notice focuses on fiduciary review, portfolio loss documentation, and lead plaintiff considerations.
New York
Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout.
New York
NEW YORK, July 28, 2026 /PRNewswire/ --Â The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
Banking Financial Services
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.Â
California
SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN)Â faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.
California
SAN FRANCISCO, July 21, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN)Â faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.
New York
NEW YORK, July 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
California
LOS ANGELES, July 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
